SecBot SecBot

RHHBY

ROCHE HOLDING AG
$61.17 +1.55 (+2.60%)
Oct 23 4:00 PM ET · prev $59.62
Median target
🔒 Subscribers only
1 year
+44.7%
from $42.27 · Oct 24
30 days
+11.6%
from $54.80
52-week range
$40.15–61.17
at the high
Avg volume 20D
1.43M
shares / day
Short interest
3.02M
+25.3%
Days to cover
1.1
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 2 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/4
Strongest BULLISH The D.C. District Court granted Genentech's petition to enforce a foreign arbitration award against…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • Short sellersBUILDING

    Short interest +25.3% to 3.02M shares. 1.1 days to cover.

  • TrendUPTREND

    11% above its 50-day average. New closing high $61.17 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
First Command Advisory Services, Inc.DOUBLED13,055$670.4K
Pacer Advisors, Inc.EXIT0$0.00
MAI Capital ManagementTRIM27,682$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trial readout
🔒 Fresh data — subscribers only
Oct 26, 2026
Trial readout
🔒 Fresh data — subscribers only
Oct 24, 2026
Trial readout
Results Pending: Crovalimab (Phase 2) — Completed 72d ago
Trial: Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal…
Oct 23, 2026
Enforcement
GENENTECH, INC. et al v. SUN PHARMACEUTICAL INDUSTRIES, LTD et al
Court ruling (njd) — Docket: 2:24-cv-10567
Oct 22, 2026
Clinical Trial
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
Phase Phase 2 — COMPLETED

Short side

FINRA· Sep 30, 2026
3,021,666
shares short
+25.3%
vs prior settlement
1.1
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Clinical trial readout
🔒 Fresh data — subscribers only
Oct 24, 2026 SEC
A New Jersey federal district court issued a Markman claim construction ruling in Genentech's ANDA litigation against…
COURT-RULING — Impact 4/10
Oct 23, 2026 Event
GENENTECH, INC. et al v. SUN PHARMACEUTICAL INDUSTRIES, LTD et al
Court ruling (njd) — Docket: 2:24-cv-10567
Oct 13, 2026 SEC
The D.C. District Court granted Genentech's petition to enforce a foreign arbitration award against Novartis…
COURT-RULING — Impact 6/10
Aug 20, 2026 Event
COTELLIC
Supplemental Approval — Labeling — COBIMETINIB — TABLET — ORAL
Aug 15, 2026 SEC
Genentech (RHHBY) won summary judgment in D.D.C. invalidating HRSA's certification of 11 clinics as 340B covered…
COURT-RULING — Impact 6/10
Jun 30, 2026 Inst.
First Command Advisory Services, — DOUBLED
13,055 shares ($670.4K)
Jun 30, 2025 Inst.
Pacer Advisors, Inc. — EXIT
0 shares ($0.00)

SecBot reports

4 filings · 2 bullish · 0 bearish · 2 neutral
All RHHBY filing & press-release reports (4)